title: Outcomes of nontransplant potentially curative therapy for early-stage hepatocellular carcinoma in Child-Pugh stage A cirrhosis is comparable with liver transplantation.
abstract: BACKGROUND
  This study was undertaken to assess the outcome of potentially curative therapy for early-stage hepatocellular carcinoma (HCC) in patients with Child-Pugh stage A cirrhosis as well as to investigate the impact of low-dose interferon (IFN) therapy after curative therapy on survival.
  
  
  METHODS
  This study retrospectively evaluated clinical outcomes in a cohort of 224 Child-Pugh stage A cirrhotic patients who received either resection (53 cases) or radiofrequency ablation (RFA: 171 cases) for HCC within Milan criteria. Thirty patients were treated with low-dose maintenance IFN therapy after initial curative therapy. The median follow-up period was 36.7 months.
  
  
  RESULTS
  The 5-year survival rate of all patients was 74.9%, with similar rates for the resection and RFA groups (70.4 vs. 76.8%; p = 0.561). The 5-year HCC recurrence rate was higher in the RFA group than the resection group (85.3 vs. 73.2%; p = 0.012). The maintenance IFN-treated group maintained their liver function within Child-Pugh stage A for a significantly longer time (median time 36.9 vs. 32.2 months; p = 0.0025).
  
  
  CONCLUSIONS
  The 5-year outcomes of resection and RFA in patients with Child-Pugh stage A cirrhosis and early stage HCC were comparable with liver transplantation. Low-dose, long-term maintenance IFN therapy after curative therapy was significantly beneficial on survival.
authors.affiliation: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kinki University School of Medicine, Ohno-Higashi, Osaka-Sayama, Japan.
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Takahashi
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Kudo
authors.forename: Hobyung
authors.initials: H
authors.lastname: Chung
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Inoue
authors.forename: Miki
authors.initials: M
authors.lastname: Nagashima
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kitai
authors.forename: Chie
authors.initials: C
authors.lastname: Tatsumi
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Minami
authors.forename: Kazuomi
authors.initials: K
authors.lastname: Ueshima
authors.forename: Toyokazu
authors.initials: T
authors.lastname: Fukunaga
authors.forename: Seiji
authors.initials: S
authors.lastname: Haji
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000998:Antiviral Agents / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000401:mortality* / Q000601:surgery*; D017115:Catheter Ablation; D005260:Female; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications / Q000473:pathology; D008113:Liver Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000601:surgery*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000628:therapy; D011379:Prognosis; D012044:Regression Analysis; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents